Andrew Nunn, Patrick Phillips, Sarah Meredith, Chen‐Yuan Chiang et al.
BACKGROUND: Cohort studies in Bangladesh showed promising cure rates among patients with multidrug-resistant tuberculosis who received existing drugs in regimens shorter than that recommended by the World Health Organization (WHO) in 2011. METHODS: at 132 weeks and at a previous occasion, with no in...
Armand Van Deun, K. J. M. Aung, Valentin Bola, Rossin Lebeke et al.
The rapid diagnosis of rifampin resistance is hampered by a reported insufficient specificity of molecular techniques for detection of rpoB mutations. Our objective for this study was to document the prevalence and prognostic value of rpoB mutations with unclear phenotypic resistance. The study desi...
Andrew Nunn, I. D. Rusen, Armand Van Deun, Gabriela Torrea et al.
BACKGROUND: In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of multi-drug-resistant tuberculosis (MDR-TB) have a very poor evidence base; current recommendations, based on expert opinion, are that patients should be treated for a minimum of 20 months. A series of cohort ...
Armand Van Deun, Valentin Bola, Rossin Lebeke, Michel Kaswa et al.
Background: The incidence of acquired rifampicin resistance (RIF-ADR; RR) during first-line treatment varies. Objectives: Compare clinically significant RIF-ADR versus primary and reinfection RR, between regimens (daily versus no rifampicin in the continuation phase; daily versus intermittent rifamp...
Andrew Nunn, I. D. Rusen, Armand Van Deun, Gabriela Torrea et al.
Background: \nIn contrast to drug-sensitive tuberculosis, the guidelines for the treatment of multi-drug-resistant \ntuberculosis (MDR-TB) have a very poor evidence base; current recommendations, based on expert opinion, are \nthat patients should be treated for a minimum of 20 months. A...